Compare · DXCM vs HTFL
DXCM vs HTFL
Side-by-side comparison of DexCom Inc. (DXCM) and Heartflow Inc. (HTFL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and HTFL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 7.8x HTFL ($4.34B).
- HTFL has been more active in the news (16 items in the past 4 weeks vs 9 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 8 for HTFL).
- Company
- DexCom Inc.
- Heartflow Inc.
- Price
- $89.16-2.09%
- $49.92-0.55%
- Market cap
- $33.65B
- $4.34B
- 1M return
- -
- +96.85%
- 1Y return
- -
- +59.31%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2025
- News (4w)
- 9
- 16
- Recent ratings
- 25
- 8
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.
Latest HTFL
- Chief Executive Officer Farquhar John C.M. sold $1,361,500 worth of shares (27,230 units at $50.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 360,814 units (SEC Form 4)
- Chief Executive Officer Farquhar John C.M. sold $1,470,420 worth of shares (32,676 units at $45.00) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 388,044 units (SEC Form 4)
- Chief Medical Officer Rogers Campbell exercised 9,219 shares at a strike of $19.00 and sold $380,099 worth of shares (9,219 units at $41.23) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Farquhar John C.M. sold $607,774 worth of shares (15,560 units at $39.06) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 420,720 units (SEC Form 4)
- SEC Form 144 filed by Heartflow Inc.
- SEC Form 144 filed by Heartflow Inc.
- SEC Form 10-Q filed by Heartflow Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Heartflow Inc.
- Heartflow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance